Limits...
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.

Li J, Saif MW - Biologics (2009)

Bottom Line: Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis.In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis.We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

View Article: PubMed Central - PubMed

Affiliation: Yale Cancer Center, Yale School of Medicine, New Haven CT, USA.

ABSTRACT
Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

No MeSH data available.


Related in: MedlinePlus

Schema of AViTA trial. 61
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747341&req=5

f2-btt-3-429: Schema of AViTA trial. 61

Mentions: OS was the primary objective, PFS, disease control rate, and toxicity were secondary objectives. Six hundred and seven patients with metastatic pancreatic cancer were randomized to receive gemcitabine/erlotinib with or without bevacizumab as initial therapy (Figure 2).


Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.

Li J, Saif MW - Biologics (2009)

Schema of AViTA trial. 61
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747341&req=5

f2-btt-3-429: Schema of AViTA trial. 61
Mentions: OS was the primary objective, PFS, disease control rate, and toxicity were secondary objectives. Six hundred and seven patients with metastatic pancreatic cancer were randomized to receive gemcitabine/erlotinib with or without bevacizumab as initial therapy (Figure 2).

Bottom Line: Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis.In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis.We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

View Article: PubMed Central - PubMed

Affiliation: Yale Cancer Center, Yale School of Medicine, New Haven CT, USA.

ABSTRACT
Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

No MeSH data available.


Related in: MedlinePlus